Immune-related adverse events, commonly called irAEs, are side effects triggered when cancer immunotherapy drugs accidentally turn the immune system against the patient’s own healthy tissues. These events can range from a mild rash that clears up on its own to life-threatening inflammation of the heart or lungs. They affect anywhere from about a quarter to over half of patients receiving immune checkpoint inhibitors, depending on the drug and whether it is used alone or in combination, and they can strike virtually any organ system in the body. Understanding the full spectrum of irAEs matters because checkpoint immunotherapy is now a frontline treatment for dozens of cancer types, and the number of people living with these side effects is growing fast.
Why Immunotherapy Causes the Body to Attack Itself
Checkpoint inhibitors work by releasing the brakes on the immune system. Normally, proteins like CTLA-4 and PD-1 sit on the surface of T cells and act as off switches, preventing immune responses from spiraling out of control. Tumors exploit these switches to hide from immune detection. Drugs that block CTLA-4 or PD-1 restore the ability of T cells to recognize and kill cancer cells, but they simultaneously disrupt the same tolerance mechanisms that keep the immune system from attacking healthy tissue.
The result is that T cells proliferate and diversify rapidly, and regulatory T cells that would normally tamp down inflammation lose their suppressive function. The body essentially becomes more sensitive to its own tissues, recognizing them as foreign targets. This is the trade-off at the heart of checkpoint therapy: the same unleashing of immune power that fights cancer can produce autoimmune-like inflammation in skin, gut, liver, lungs, endocrine glands, joints, and even the heart.1Frontiers in Immunology. Immune-related adverse events of immune checkpoint inhibitors: a review
Different drugs produce somewhat different patterns. CTLA-4 inhibitors like ipilimumab are more closely linked to colitis and diarrhea, while PD-1 inhibitors such as nivolumab and pembrolizumab tend to produce a broader range of immune-mediated side effects including thyroid problems and pneumonitis.2PubMed Central. Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database When PD-1 and CTLA-4 inhibitors are used together, the rate of severe side effects climbs sharply, with roughly three in five patients on combination therapy experiencing a serious adverse event.3PubMed Central. Checkpoint Inhibitors
Organs in the Crosshairs
The most commonly affected systems are the skin, gastrointestinal tract, liver, and endocrine glands.4Nature Reviews Clinical Oncology. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination But irAEs have been documented in nearly every organ, including the kidneys, pancreas, joints, nervous system, and heart. Here is what that looks like in practice.
Skin
Skin reactions are the most frequent irAEs and often the earliest to appear. The most common presentations include a flat, blotchy rash (maculopapular rash), itching, and scaly eruptions that resemble psoriasis or lichen planus. Maculopapular rash tends to show up within the first six weeks of treatment. More distinctive reactions, like patches of skin losing their pigment in a pattern resembling vitiligo, or blistering conditions, are more closely tied to PD-1 inhibitors specifically.5PubMed Central. Immune checkpoint inhibitor-related dermatologic adverse events Rarely, severe reactions like Stevens-Johnson syndrome can occur, requiring hospitalization and emergency dermatology care.6Frontiers in Immunology. Cutaneous manifestations associated with immune checkpoint inhibitors
Gut and Liver
Diarrhea and colitis are among the most clinically significant irAEs, particularly with CTLA-4 inhibitors. The inflammation can range from mild, self-limiting diarrhea to severe colitis that, in extreme cases, requires surgery. The liver can also become inflamed, a condition known as immune-mediated hepatitis, which is detected through rising liver enzymes on blood tests. Over-activation of the immune system can affect both the GI tract and the liver simultaneously.7PubMed Central. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
Endocrine Glands
Thyroid disorders, including both overactive and underactive thyroid, are among the most common endocrine irAEs. But the endocrine story has a wrinkle that sets it apart from other organ-system effects: once checkpoint inhibitors damage an endocrine gland, the damage is usually permanent. The gland stops producing adequate hormones, and patients need lifelong hormone replacement.8The Oncologist. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events Hypophysitis, inflammation of the pituitary gland, is a particular concern with CTLA-4 inhibitors. When the pituitary is affected, the adrenal axis almost never recovers, meaning patients typically need cortisol replacement for life, though thyroid and sex-hormone production may eventually bounce back and should be periodically re-evaluated.9The Journal of Clinical Endocrinology & Metabolism. Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease The good news is that endocrine irAEs, once properly managed with hormone replacement, have a fairly small impact on quality of life and usually do not force patients to stop cancer treatment.8The Oncologist. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
Heart, Lungs, Joints, and Beyond
Rarer irAEs include pneumonitis (lung inflammation, occurring in roughly 3 to 8 percent of patients), nephritis, and cardiac inflammation.3PubMed Central. Checkpoint Inhibitors Myocarditis, inflammation of the heart muscle, is uncommon, affecting just over 1 percent of patients, but it is disproportionately dangerous. In one study, nearly half of patients who developed checkpoint-related myocarditis experienced a major adverse cardiac event, and this happened even in patients whose heart-pumping function appeared normal on imaging.10PubMed Central. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors Joint inflammation is also increasingly recognized: inflammatory arthritis, polymyalgia-like syndromes, and myositis have all been linked to checkpoint therapy. Myositis can be especially tricky because it sometimes comes bundled with cardiac inflammation or a condition resembling myasthenia gravis, requiring aggressive treatment with steroids and sometimes plasma exchange.11PubMed Central. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
When Do irAEs Show Up
Most irAEs appear within the first few months of treatment, but timing varies by organ. Skin reactions tend to come first, often within weeks. Colitis and hepatitis typically follow weeks to months later. Endocrine problems can emerge at any point. The conventional expectation used to be that irAEs were early events, but research has forced a rethinking. One study tracking patients over two years found that the cumulative probability of developing an irAE kept climbing steadily: about 43 percent at six months, 51 percent at one year, and 57 percent at two years.12PubMed. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
Late-onset irAEs, those appearing months or even years after the last dose, are real and probably underappreciated. In a melanoma cohort, about 14 percent of patients developed an irAE more than three months after their final dose of anti-PD-1 therapy.13PubMed. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma Late-onset myocarditis is a particularly sobering example: a systematic review of late-presenting cases found a median onset of nine months, with some cases appearing more than two years after treatment began, and over a third of those patients had already stopped taking the checkpoint inhibitor when the heart problem surfaced.14PubMed. Late-onset immune checkpoint inhibitor-associated myocarditis: A systematic review and patient-level synthesis The practical takeaway is that vigilance cannot end when treatment ends.
The Paradox of Side Effects Predicting Better Outcomes
One of the more counterintuitive findings in checkpoint immunotherapy is that patients who develop irAEs tend to live longer and respond better to treatment than those who do not. A systematic review and meta-analysis that pooled data across melanoma and lung cancer patients found consistently better outcomes in people who experienced irAEs. In lung cancer, patients with irAEs had a median overall survival of about 19 months compared with roughly 7.5 months for those without, and their response rates were more than double.15PubMed. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis Similar patterns held in melanoma, renal cell carcinoma, and other cancers.
In a smaller single-center study of non-small cell lung cancer patients, those with severe (grade 3 or higher) irAEs had a 68 percent response rate to treatment compared with 20 percent in those with milder or no side effects, and one-year survival rates were highest in the severe-irAE group.16PubMed Central. Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer The logic makes intuitive sense: if the drug is powerfully activating the immune system, that activation may hit both the tumor and normal tissue. A strong autoimmune reaction may signal a strong antitumor reaction.
Still, this does not mean that provoking side effects is a goal. The association between irAEs and better outcomes is observational, meaning it could partly reflect the fact that patients who stay on therapy long enough to develop side effects are healthier to begin with. And some of the most dangerous irAEs, like myocarditis, are associated with significant morbidity regardless of any potential survival benefit. Clinicians use this correlation as a prognostic signal, not a treatment strategy.17Frontiers in Medicine. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
How irAEs Are Managed
The standard approach to managing irAEs follows a grading system based on severity. Mild reactions (grade 1) often require only symptom management and close monitoring. More troublesome grade 2 events may call for pausing the checkpoint inhibitor and starting moderate doses of corticosteroids. Grade 3 or higher toxicities generally require stopping the immunotherapy drug, beginning high-dose steroids, and tapering those steroids slowly over at least four to six weeks to avoid a rebound flare.18PubMed. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
When steroids alone are not enough, the situation gets more complicated. Infliximab, a drug borrowed from rheumatology, is a common second-line agent for steroid-refractory colitis. But some patients fail that, too. A multicenter study of patients with checkpoint-related GI toxicity that did not respond to infliximab found that calcineurin inhibitors resolved symptoms in about three-quarters of cases and worked the fastest (a median of 12 days to resolution). Vedolizumab, a gut-targeted biologic, took much longer to work (about 66 days) but was associated with the best survival outcomes among the options studied.19PubMed Central. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series In the most extreme cases, colectomy was needed. These choices illustrate the real clinical tension: the fastest fix for immune toxicity is often the most broadly immunosuppressive, which raises its own risks for a cancer patient.
Restarting Immunotherapy After a Serious Reaction
When a patient’s cancer is responding to checkpoint therapy but an irAE forces treatment to stop, the question of whether to restart the drug is one of the hardest calls in oncology. The evidence suggests it is often feasible, but far from risk-free. In a renal cell carcinoma cohort, half of patients who were re-challenged with a checkpoint inhibitor after a significant irAE went on to develop another immune-related side effect. Two-thirds of those second events were a new type of irAE rather than a recurrence of the original one, and all were grade 3 or lower with no fatal events.20PubMed Central. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
The recurrence risk varies by the type of original irAE. Colitis appears to be among the less likely to come back on rechallenge (roughly 6 percent recurrence in one dataset), whereas hepatitis, pancreatitis, and pneumonitis recur more often. A study of patients switched to single-agent anti-PD-1 after combination therapy toxicity found that 50 percent experienced some grade of new adverse event, though most were manageable. When the same checkpoint inhibitor class was resumed, about 43 percent of patients experienced a recurrent irAE of the same type, while 12.5 percent experienced a different one. Reassuringly, the second irAE was generally no more severe than the first.21Journal for ImmunoTherapy of Cancer. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy These numbers give both oncologists and patients a basis for a shared decision, weighing the cancer’s trajectory against the known risks of retreatment.
People With Pre-existing Autoimmune Diseases
Patients with conditions like rheumatoid arthritis, lupus, or inflammatory bowel disease were historically excluded from checkpoint inhibitor clinical trials, leaving doctors to fly blind when these patients needed immunotherapy. Real-world data is now filling that gap, and the news is mixed but more optimistic than many feared. A systematic review found that about 53.5 percent of patients with pre-existing autoimmune diseases experienced some grade of irAE, with about 34 percent having a flare of their underlying autoimmune condition and about 28 percent developing an entirely new immune-mediated side effect. Treatment had to be stopped for toxicity in about 15 percent, and fatal events were rare, occurring in about 0.5 percent.22PubMed Central. Safety and effectiveness of immune checkpoint inhibitors in patients with preexisting autoimmune diseases: a systematic review
Flare risk depends heavily on which autoimmune disease someone has. Patients with rheumatoid arthritis, polymyalgia rheumatica, and psoriatic arthritis face the highest reported flare rates, up to 75 percent, though flares tend to be mild.23Nature Reviews Rheumatology. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases The overall message from the accumulating data is that a pre-existing autoimmune disease is not an absolute barrier to receiving checkpoint therapy, but it does demand closer surveillance and earlier intervention.
Age and irAE Risk
Older adults make up the majority of cancer patients receiving checkpoint inhibitors, yet the relationship between age and irAE risk is not straightforward. One study comparing older patients (65 and above) with younger patients found that the incidence of moderate-to-severe irAEs was higher in the older group (33 percent versus 25 percent), and older patients were more prone to having multiple irAEs at once. Interestingly, skin toxicities were more frequent in older patients, while endocrine side effects were actually less common. Despite the higher irAE rates, there was no significant survival difference between the age groups.24PubMed. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies
The aging immune system undergoes changes that could cut both ways. Some researchers have proposed that the age-related shift in immune-cell populations and the chronic low-grade inflammation that accompanies aging could make irAEs more likely in some organ systems while blunting antitumor efficacy.25Cancer Pathogenesis and Therapy. Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors But clinical data has not shown dramatically worse outcomes in older patients, so age alone is not treated as a reason to withhold these drugs.
The Gut Microbiome as a Crystal Ball
Predicting which patients will develop irAEs before they happen is one of the most active research fronts in this space. The gut microbiome has emerged as an especially promising predictor. A study that built a machine-learning classifier using 14 bacterial species from stool samples could distinguish between patients who did and did not develop irAEs with an area under the curve of 0.88, a strong signal for a biological test.26PubMed Central. Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Specific bacterial populations appear to tilt the odds. In GI cancer patients on checkpoint inhibitors, species like Bacteroides massiliensis and Parabacteroides distasonis were more abundant in patients who avoided irAEs, while species like Bifidobacterium dentium and Rothia mucilaginosa were enriched in those who developed them.27Frontiers in Cellular and Infection Microbiology. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors These findings are not yet part of routine clinical practice, but they point toward a future in which a stool sample before starting immunotherapy could help personalize monitoring plans.
On the digital side, machine-learning models that analyze patient-reported symptom data from electronic questionnaires have also shown promise for catching irAEs early. One system deployed in melanoma patients generated alerts that detected about a third of grade 2-or-higher irAEs before the patient’s next scheduled clinic visit, saving an average of four days of lead time.28ESMO Real World Data and Digital Oncology. Real-world evaluation of ImmuCare-PRO patient-reported outcomes in melanoma patients treated with immune checkpoint inhibitors Four days may not sound like much, but for a condition like myocarditis, early detection can be the difference between a manageable episode and a fatal one.
Living With Chronic irAEs
As checkpoint inhibitors produce more long-term survivors, a new question is taking center stage: what do irAEs look like years later? The evidence suggests that roughly 20 to 30 percent of survivors carry late or long-lasting immune side effects.29PubMed Central. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review The most common chronic irAE is hypothyroidism, found in about 11 percent of long-term survivors in one cohort, followed by arthritis, adrenal insufficiency, and nerve damage.30PubMed Central. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
Quality of life among long-term survivors is, on the whole, good. Self-reported outcomes compare favorably to the general population, though about 40 percent of survivors report some degree of anxiety or depression and about 31 percent report ongoing pain or discomfort.31PubMed Central. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors The irony is that surviving a previously incurable cancer through immunotherapy can leave you trading one chronic condition for another: a person cured of melanoma may end up on thyroid medication for the rest of their life. For most, that trade is well worth making, but it underscores the importance of survivorship care plans that account for ongoing irAE monitoring.
The Financial Weight of irAEs
The clinical burden of irAEs comes with a substantial price tag. A study of non-small cell lung cancer patients found that those who developed clinically significant irAEs had more than double the odds of being hospitalized compared with those who did not. Their average monthly medical costs ran about $3,300 higher, driven primarily by inpatient care. Over two years, cumulative costs per patient were roughly $94,000 higher in the irAE group.32PubMed Central. Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non-small cell lung cancer A separate analysis across cancer types estimated that adjusted six-month costs were about $24,000 higher for patients with adverse events, with inpatient stays accounting for the vast majority of that difference.33The Oncologist. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors These figures make the case for early detection and smarter prevention strategies not only clinical but economic.
Newer Checkpoint Targets and Their Side-Effect Profiles
The next generation of checkpoint inhibitors is targeting molecules beyond PD-1 and CTLA-4, including LAG-3, TIGIT, TIM-3, and CD40. Early data suggest these agents carry their own distinct toxicity signatures rather than simply mimicking existing drugs. A meta-analysis of trials involving these newer agents found that adding LAG-3 blockade to PD-1-based therapy significantly increased the risk of severe adverse events, with particular signals for adrenal insufficiency and joint pain. TIGIT blockade, when layered onto PD-L1 therapy, was linked to increased rates of rash. TIM-3 blockers showed the highest rates of severe pneumonitis and hepatitis among the newer targets, while CD40 agonists had the most skin toxicity.34Journal of Clinical Oncology. Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis Combination regimens involving kidney-targeted toxicity are also emerging as a concern: a pharmacovigilance analysis of the FDA’s adverse-event database flagged strong signals for glomerular kidney injury and pancreatic toxicity when ipilimumab and nivolumab were combined.35Frontiers in Immunology. Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system
As the immunotherapy toolkit expands, so does the vocabulary of possible side effects. The spectrum of irAEs is not a fixed list. It is a moving target that grows with each new drug and combination, and clinicians managing these patients need to keep learning alongside it.